Safety of revaccination with pneumococcal polysaccharide vaccine

JAMA. 1999 Jan 20;281(3):243-8. doi: 10.1001/jama.281.3.243.

Abstract

Context: Revaccination of healthy adults with pneumococcal polysaccharide vaccine (PPV) within several years of first vaccination has been associated with a higher than expected frequency and severity of local injection site reactions. The risk of adverse events associated with revaccination of elderly and chronically ill persons 5 or more years after first vaccination, as is currently recommended, has not been well defined.

Objective: To determine whether revaccination with PPV at least 5 years after first vaccination is associated with more frequent or more serious adverse events than those following first vaccination.

Design: Comparative intervention study conducted between April 1996 and August 1997.

Participants: Persons aged 50 to 74 years either who had never been vaccinated with PPV (n = 901) or who had been vaccinated once at least 5 years prior to enrollment (n = 513).

Intervention: PPV vaccination.

Main outcome measures: Postvaccination local injection site reactions and prevaccination concentrations of type-specific antibodies.

Results: Those who were revaccinated were more likely than those who received their first vaccinations to report a local injection site reaction of at least 10.2 cm (4 in) in diameter within 2 days of vaccination: 11% (55/513) vs 3% (29/901) (relative risk [RR], 3.3; 95% confidence interval [CI], 2.1-5.1). These reactions resolved by a median of 3 days following vaccination. The highest rate was among revaccinated patients who were immunocompetent and did not have chronic illness: 15% (33/228) compared with 3% (10/337) among comparable patients receiving their first vaccinations (RR, 4.9; 95% CI, 2.4-9.7). The risk of these local reactions was significantly correlated with prevaccination geometric mean antibody concentrations.

Conclusions: Physicians and patients should be aware that self-limited local injection site reactions occur more frequently following revaccination compared with first vaccination; however, this risk does not represent a contraindication to revaccination with PPV for recommended groups.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Antibodies, Bacterial / biosynthesis
  • Bacterial Vaccines / administration & dosage*
  • Bacterial Vaccines / adverse effects*
  • Bacterial Vaccines / immunology
  • Female
  • Humans
  • Immunization Schedule
  • Immunocompetence
  • Immunocompromised Host
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pneumococcal Vaccines
  • Streptococcus pneumoniae / immunology*
  • Time Factors

Substances

  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Pneumococcal Vaccines